Skip to search formSkip to main contentSkip to account menu

CP 547632

Known as: CP-547,632, CP-547632, CP547,632 
A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called vascular endothelial growth factor (VEGF… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors
Abstract Literature data on the clinical pharmacokinetics of various VEGFR-2 inhibitors along with in vitro potency data were… 
2007
2007
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment…
PurposeTo evaluate the toxicity profile and pharmacological properties of oral CP-547,632 alone and in combination with… 
2006
2006
YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors
Purpose: The vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase has been implicated in the pathologic… 
Review
2005
Review
2005
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
The treatment of lung cancer remains a significant challenge. Although chemotherapy remains the standard approach, a plateau has… 
2005
2005
In vivo TargetModulation and Biological Activity of CHIR-258 , aMultitargeted Growth Factor Receptor Kinase Inhibitor , in Colon CancerModels
Purpose:To evaluate the therapeutic and biological effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V… 
2004
2004
Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC).
3014 Background: Overexpression of vascular endothelial growth factor (VEGF) portends a poor outcome in NSCLC. Tumor angiogenesis… 
2004
2004
137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors
Review
2004
Review
2004
Recent developments in the discovery of protein kinase inhibitors from the urea class.
With two compounds on the market (Gleevec and Iressa), and a number of drug candidates in late-stage clinical trials, small… 
Highly Cited
2003
Highly Cited
2003
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Signaling through vascular endothelial growth factor (VEGF) receptors (VEGFRs) is a key pathway initiating endothelial cell… 
Review
2003
Review
2003
Angiogenesis inhibitors under study for the treatment of lung cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)